This study is being done in unresectable Stage III non-small cell lung cancer, which means a type of lung cancer that cannot be removed with surgery and has not gotten worse after earlier treatment with platinum-based concurrent chemoradiation therapy (chemotherapy and radiation given at the same time). The study compares pumitamig with durvalumab to see which medicine is better at slowing the cancer from getting worse. Pumitamig is given into a vein as an infusion, and durvalumab is also given into a vein.
After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.
1joining the study and starting treatment
after joining the study, you enter a randomized trial. this means the study assigns you to receive either pumitamig or durvalumab. the study is also open-label, which means you and the study team know which medicine you receive.
both medicines are given by intravenous infusion, meaning they are administered into a vein.
pumitamig is given as bnt327 50 mg/ml or bnt327 20 mg/ml, depending on the assigned study treatment.
the study does not provide a dose amount, dosing schedule, or treatment duration in the source data beyond the fact that the medicines are given during the trial.
2receiving the assigned medicine during the trial
if you are assigned to pumitamig, you receive it by intravenous infusion. the source data identifies the product as bnt327 50 mg/ml or bnt327 20 mg/ml, with the active substance pumitamig.
if you are assigned to durvalumab, you receive it by intravenous infusion. the active substance is durvalumab.
the source data does not state the exact dose, frequency, or length of treatment for either medicine.
3monitoring the effect of treatment
during the trial, your cancer is checked to see whether it stays the same, shrinks, or grows.
the main measure is progression-free survival (pfs), which means the length of time before the cancer gets worse. bicr means an independent review of scans or test results used to judge this outcome.
the study also looks at overall survival (os), which means how long you live after starting treatment.
your doctor also checks progression-free survival, called pfs by investigator, which means the time before the cancer gets worse as judged by your doctor.
the study measures whether tumors shrink, disappear, stay the same size, or remain controlled. these are called objective response (or) and disease control rate (dcr).
the study measures duration of response (dor), which means how long the tumor stays smaller or stable after it improves.
the study measures time to response (ttr), which means how quickly the tumor starts to shrink after treatment begins.
the study also checks safety and how well you can tolerate each medicine.
4continuing follow-up during the study period
you remain in the study while treatment and follow-up continue for the trial period.
the source data gives the overall study timeframe as starting on 2026-05-11 and ending on 2034-01-12.
no further step-by-step schedule is provided in the source data.
Who Can Join the Study?
Have unresectable Stage III non-small cell lung cancer, which means the cancer cannot be removed with surgery and is at stage 3.
Have had chemoradiation before joining the study, meaning treatment with both chemotherapy and radiation therapy.
Have no worsening of the cancer after chemoradiation.
May have any level of PD-L1 expression, meaning the cancer cells can have low, medium, or high amounts of the PD-L1 protein.
Be in good overall health, meaning the person is well enough to take part in the study treatment.
Who Cannot Join the Study?
Any significant heart or blood vessel disease, meaning a serious problem affecting the heart or circulation.
Any significant lung disease within the 6 months before randomization, meaning before being assigned to a study group.
A history of interstitial lung disease, which is scarring or inflammation in the tissue around the air sacs of the lungs.
A history of pneumonitis that needed treatment with systemic steroids, meaning steroid medicine taken by mouth or given through a vein to treat inflammation in the lungs.
A high risk of pulmonary hemorrhage, meaning a serious risk of bleeding from the lungs.
A history of abdominal fistula within the 6 months before randomization, meaning an abnormal tunnel between the abdomen and another organ or the skin.
A history of gastrointestinal perforation within the 6 months before randomization, meaning a hole in the stomach or intestines.
Having certain gene changes called EGFR mutations, which are changes in a gene that can affect how cancer grows.
Having certain gene changes called ALK rearrangements, which are changes in a gene that can affect how cancer grows.
Any major coagulation disorder, meaning a serious problem with blood clotting.
Pumitamig is the study treatment being tested in this trial. It is given through a vein as an infusion. The goal is to see whether it can help slow down the cancer from getting worse after prior chemoradiation treatment in people with unresectable stage III non-small cell lung cancer.
Durvalumab is the comparison treatment in this trial. It is also given through a vein as an infusion. The study is checking whether pumitamig works better than durvalumab at keeping the cancer from progressing after earlier platinum-based chemoradiation therapy.
Unresectable stage III non-small cell lung cancer – A form of lung cancer that starts in the cells lining the airways or lung tissue and cannot be removed completely by surgery. It is at stage III, meaning it has grown beyond the original lung area and may involve nearby lymph nodes or nearby structures. When it is without progression, the cancer has not shown signs of getting worse at the time described. Over time, it may remain stable for a period or begin to grow, spread locally, or cause new tumor areas to appear.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Bulgaria 
France 
Germany 
Greece 
Hungary 
Ireland 
Italy 
Poland 
Romania 
Spain 
Sweden 
The Netherlands 
